Snake Anti-Venom

Since early 1900s when the first antivenom polyclonal antibodies were developed, no signficant progress was made in antivenom development despite advances in monoclonal therapeutics. We at mAbGenEx are revolutionizing antivenom development using monoclonals against Common Krait. This project is supported by BIRAC-BIG.

Oncology

With a focus on oncology, we are advancing the development of novel antibody-based therapeutics targeting G-protein-coupled receptors (GPCRs) to address unmet medical needs in cancer treatment.